| Sep 17 |
ESMO 2024: Eli Lilly brings the competition to Novartis with new results in mCRPC
|
| Sep 17 |
Lilly Gets FDA Approval for Eczema Drug Ebglyss
|
| Sep 16 |
Valeo Pharma Inc (VPHIF) Q3 2024 Earnings Call Transcript Highlights: Revenue Decline and ...
|
| Sep 16 |
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
|
| Sep 16 |
Novartis’ breast cancer trial of Kisqali reveals 28.5% risk reduction
|
| Sep 16 |
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
|
| Sep 14 |
J&J leads H1 healthcare deals as Big Pharma dealmaking returns: report
|
| Sep 12 |
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
|
| Sep 11 |
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
|
| Sep 11 |
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
|
